Multicenter Prospective Registry Study of Diffuse Large B Cell Lymphoma

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02474550

Enrollment

1000

Registered

2015-06-17

Start date

2015-04-30

Completion date

2020-12-31

Last updated

2017-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diffuse Large B Cell Lymphoma, Neutropenia, Febrile

Keywords

diffuse large b cell lymphoma, peg-filgrastim, febrile neutropenia

Brief summary

This study was designed to review clincal outcomes of Diffuse Large B Cell Lymphoma (DLBCL) treated with R-CHOP chemotherapy in the era of pegylated-filgrastim. The investigators will prospectively collect clinical data and treatment outcome of patients with DLBCL who use prophylactic pegylated-filgrastim.

Detailed description

* Newly diagnosed DLBCL patients treated with R-CHOP chemotherapy * Prphylactic peg-filgrastim on the day after chemotherapy

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Healthy volunteers

Inclusion criteria

* 19 or older * newly diagnosed with DLBCL * R-CHOP chemotherapy * offer informed consent

Exclusion criteria

* other subtype of NHL * concomitant other cancer * previous chemotherapy or radiotherapy

Design outcomes

Primary

Measure	Time frame
incidence of febrile neutropenia	within 30 days

Secondary

Measure	Time frame
incidence of chemotherapy-related adverse events other than febrile neutropenia	4 weeks after completion of chemotherapy
Overall survival	2 year

Countries

South Korea

Contacts

Primary ContactGeum-Sook Jeong

geumsook@ajou.ac.kr+82-31-219-5989

Outcome results